Melatonin plays a role in blood pressure (BP) control. The aim of this study was to determine whether melatonin concentrations and melatonin receptor levels are altered in L-NAME-treated, NO-deficient hypertensive rats. Two groups of male adult Wistar rats were investigated: rats (n¼36) treated with NO-synthase inhibitor L-NAME (40 mg kg À1 ) and age-matched controls (n¼36). BP was measured weekly by tail-cuff plethysmography. After 4 weeks, L-NAME administration increased BP (178±1 vs. control 118 ± 1 mm Hg). At the end of treatment, rats were killed in regular 4 h intervals over a 24-h period. Melatonin concentrations in the plasma, pineal gland, heart and kidney and melatonin receptor (MT 1 ) density in the aorta were determined. A significant daily rhythm of melatonin concentrations was found in the blood, pineal gland, kidney and heart of both control and hypertensive rats. Peak nighttime pineal melatonin concentrations were higher in L-NAME-treated rats than in controls (3.38 ± 0.48 vs. 1.75 ± 0.33 ng per pineal gland). No differences between both groups were found in melatonin concentrations in blood, kidney and heart or in the MT 1 receptor density in the aorta. Our results suggest that L-NAME treatment enhances melatonin production in the pineal gland, potentially by decreasing an inhibitory effect of NO on melatonin production in the pineal gland. However, the enhanced pineal melatonin formation was insufficient to increase melatonin concentrations in circulation, heart and kidney of L-NAME-treated rats, indicating an increased use of melatonin in hypertensive animals.
INTRODUCTIONMelatonin is a hormone produced by the pineal gland in a circadian manner and exhibits a broad spectrum of effects, including those in the cardiovascular system. Melatonin has been suggested to play a role in blood pressure (BP) control. Earlier reports have shown that pinealectomized rats developed hypertension, 1 and the administration of melatonin in this model normalized the increased BP. 2 Melatonin decreased BP in hypertensive patients, 3 and the addition of melatonin to antihypertensive medication in patients with nocturnal hypertension reduced nighttime systolic BP. 4 However, the mechanisms behind melatonin's effect on BP are still not completely understood.The hypotensive effect of melatonin could be mediated either by a direct effect on vessels or by decreasing brain serotonin release, resulting in sympathetic inhibition or parasympathetic stimulation. 5 There are rather limited data about changes of melatonin concentrations related to essential hypertension in the literature. Plasma melatonin and urinary 6-sulfatoxymelatonin levels have been reported